» Articles » PMID: 31269811

Quantitative Myocardial Perfusion in Fabry Disease

Abstract

Background: Fabry disease (FD) is an X-linked lysosomal storage disease resulting in tissue accumulation of sphingolipids. Key myocardial processes that lead to adverse outcomes in FD include storage, hypertrophy, inflammation, and fibrosis. These are quantifiable by multiparametric cardiovascular magnetic resonance. Recent developments in cardiovascular magnetic resonance perfusion mapping allow rapid in-line perfusion quantification permitting broader clinical application, including the assessment of microvascular dysfunction. We hypothesized that microvascular dysfunction in FD would be associated with storage, fibrosis, and edema.

Methods: A prospective, observational study of 44 FD patients (49 years, 43% male, 24 [55%] with left ventricular hypertrophy [LVH]) and 27 healthy controls with multiparametric cardiovascular magnetic resonance including vasodilator stress perfusion mapping. Myocardial blood flow (MBF) was measured and its associations with other processes investigated.

Results: Compared with LVH- FD, LVH+ FD had higher left ventricular ejection fraction (73% versus 68%), more late gadolinium enhancement (85% versus 15%), and a lower stress MBF (1.76 versus 2.36 mL/g per minute). The reduction in stress MBF was more pronounced in the subendocardium than subepicardium. LVH- FD had lower stress MBF than controls (2.36 versus 3.00 mL/g per minute; P=0.002). Across all FD, late gadolinium enhancement and low native T1 were independently associated with reduced stress MBF. On a per-segment basis, stress MBF was independently associated with wall thickness, T2, extracellular volume fraction, and late gadolinium enhancement.

Conclusions: FD patients have reduced perfusion, particularly in the subendocardium with greater reductions with LVH, storage, edema, and scar. Perfusion is reduced even without LVH suggesting it is an early disease marker.

Citing Articles

Role of Cardiac Magnetic Resonance in Inflammatory and Infiltrative Cardiomyopathies: A Narrative Review.

Marchetti D, Buzzi F, Di Febo R, Modugno S, Schillaci M, Paolisso P J Clin Med. 2024; 13(16).

PMID: 39200875 PMC: 11355574. DOI: 10.3390/jcm13164733.


Cardiac Magnetic Resonance Features of Fabry Disease: From Early Diagnosis to Prognostic Stratification.

Camporeale A, Diano A, Tondi L, Pica S, Pasqualin G, Ciabatti M Rev Cardiovasc Med. 2024; 23(5):177.

PMID: 39077600 PMC: 11273773. DOI: 10.31083/j.rcm2305177.


The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies.

Pieroni M, Ciabatti M, Graziani F, Camporeale A, Saletti E, Lillo R Rev Cardiovasc Med. 2024; 23(6):196.

PMID: 39077177 PMC: 11273771. DOI: 10.31083/j.rcm2306196.


Fabry Disease Cardiomyopathy: A Review of the Role of Cardiac Imaging from Diagnosis to Treatment.

Fuertes Kenneally L, Garcia-Alvarez M, Feliu Rey E, Garcia Barrios A, Climent-Paya V Rev Cardiovasc Med. 2024; 23(6):192.

PMID: 39077169 PMC: 11273868. DOI: 10.31083/j.rcm2306192.


Echocardiography in Anderson-Fabry Disease.

Lillo R, Pieroni M, Camporeale A, Ciabatti M, Lombardo A, Massetti M Rev Cardiovasc Med. 2024; 23(6):201.

PMID: 39077168 PMC: 11274060. DOI: 10.31083/j.rcm2306201.


References
1.
Messroghli D, Moon J, Ferreira V, Grosse-Wortmann L, He T, Kellman P . Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular.... J Cardiovasc Magn Reson. 2017; 19(1):75. PMC: 5633041. DOI: 10.1186/s12968-017-0389-8. View

2.
Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici P . Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003; 349(11):1027-35. DOI: 10.1056/NEJMoa025050. View

3.
Thurberg B, Rennke H, Colvin R, Dikman S, Gordon R, Collins A . Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002; 62(6):1933-46. DOI: 10.1046/j.1523-1755.2002.00675.x. View

4.
Neglia D, Fommei E, Varela-Carver A, Mancini M, Ghione S, Lombardi M . Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens. 2010; 29(2):364-72. DOI: 10.1097/HJH.0b013e328340a08e. View

5.
Hansen M, Sorensen T . Gadgetron: an open source framework for medical image reconstruction. Magn Reson Med. 2012; 69(6):1768-76. DOI: 10.1002/mrm.24389. View